PTAB’s Ruling on Spruce Biosciences’ Patent Threatens Biotech IP Stability

The Patent Trial and Appeal Board (PTAB) has ruled that the patent claims held by Spruce Biosciences Inc. related to a hormone treatment are invalid. This finding was reached after Neurocrine Biosciences Inc. successfully demonstrated the invalidity of all the claims put forth by Spruce Biosciences. The implications of this decision resonate within the biotechnology sector as it highlights the scrutiny patents face regarding their validity, particularly those involving specialized treatments. For further details on the PTAB’s decision, see the full account here.